SYRESpyre Therapeutics, Inc.

$93.63

Who owns SYRE

195 institutions reported holding SYRE for 2026Q1, together 105% of the company, more than the 152 a quarter earlier.

195

Institutions reporting a position · as of 2026Q1 · up from 152 the quarter before

Shares held by institutions
82.5M

Shares held by institutions · 105% of the company · long US equity positions only, as reported on Form 13F

Reported value
$4.15B

Reported value · at 2026-03-31 prices, not today's

Top 5 holders
38%

Top 5 holders · of the whole company, between five filers

Details
Reporting quarter2026-03-31
2026Q1
Quarters on record
11
New positions
49
Positions exited
13
Added to
63
Reduced
46
Top 10 holdersof the company
56%
Institutional ownership by quarter, 2023Q3 to 2026Q1
QuarterFilersSharesReported value
2026Q119582.5M$4.15B
2025Q415281.0M$2.65B
2025Q313564.3M$1.08B
2025Q212863.6M$953M
2025Q112862.1M$1.00B
2024Q412959.9M$1.39B
2024Q311951.4M$1.51B
2024Q210750.4M$1.18B
2024Q110231.6M$1.20B
2023Q45428.0M$601M
2023Q3263.3M$40M
Largest reported holders, 2026Q1
HolderShares% of companyValue
FMR LLC11.8M15%$594M
BlackRock Inc.5.5M7.0%$278M
VANGUARD GROUP INC4.2M5.3%$211M
RTW INVESTMENTS, LP4.2M5.3%$210M
Fairmount Funds Management LLC4.0M5.1%$203M
PERCEPTIVE ADVISORS LLC3.8M4.8%$191M
Venrock Adviser, LLC3.7M4.7%$186M
Driehaus Capital Management LLC2.8M3.5%$141M
STATE STREET CORP2.6M3.3%$131M
Paradigm Biocapital Advisors LP2.0M2.5%$99M

SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.

reading the register…